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Heparan sulfate in the glomerular basement membrane has
been considered crucial for charge-selective filtration. In many
proteinuric diseases, increased glomerular expression of
heparanase is associated with decreased heparan sulfate.
Here, we used mice overexpressing heparanase and evaluated
the expression of different heparan sulfate domains in the
kidney and other tissues measured with anti-heparan sulfate
antibodies. Glycosaminoglycan-associated anionic sites were
visualized by the cationic dye cupromeronic blue. Transgenic
mice showed a differential loss of heparan sulfate domains in
several tissues. An unmodified and a sulfated heparan sulfate
domain resisted heparanase action in vivo and in vitro.
Glycosaminoglycan-associated anionic sites were reduced
about fivefold in the glomerular basement membrane of
transgenic mice, whereas glomerular ultrastructure and renal
function remained normal. Heparanase-resistant heparan
sulfate domains may represent remnant chains or chains not
susceptible to cleavage. Importantly, the strong reduction of
glycosaminoglycan-associated anionic sites in the glomerular
basement membrane without development of a clear renal
phenotype questions the primary role of heparan sulfate in
charge-selective filtration. We cannot, however, exclude that
overexpression of heparanase and heparan sulfate loss in the
basement membrane in glomerular diseases contributes to
proteinuria.
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Heparan sulfate proteoglycans are expressed at the surface of
virtually all cells and in the extracellular matrix. Heparan
sulfate proteoglycans consist of a core protein with linear
covalently attached heparan sulfate (HS) sugar side chains
that belong to the family of strong negatively charged
glycosaminoglycans that also includes heparin and non-
sulfated hyaluronan. The HS chain comprises up to 150
a(1–4)-glucuronate-b(1–4)-N-acetyl-glucosamine disacchar-
ide units that can be modified extensively. Modifications of
HS include N-deacetylation/N-sulfation of N-acetylglucos-
amine; C-5 epimerization of glucuronic acid to iduronic acid;
and 2-O-, 3-O-, and 6-O-sulfation. The structure of the HS
chains may be edited by HS-modifying enzymes that include
heparanase, a b(1–4)-endoglucuronidase that cleaves HS at
specific sites, and HS 6-O-endosulfatases that specifically
remove 6-O-sulfate. The combination of possible modifica-
tions gives rise to an enormous structural diversity of the HS
chain, which dictates the binding and modulation of a
myriad of factors that include growth factors, chemokines,
cytokines, enzymes, and structural proteins. These HS-bound
factors are key mediators in many biological and pathological
processes.1,2
For several decades, it has been hypothesized that the
negatively charged HS in the glomerular basement mem-
brane (GBM) is crucial for the charge-selective permeability
of the glomerular capillary filter. Seminal studies by
Farquhar, Kanwar, and co-workers demonstrated the pre-
sence of glycosaminoglycans, including HS, in the GBM,
whereas removal of glycosaminoglycans in the GBM by
perfusion of bacterial glycosaminoglycan-degrading enzymes
led to the passage of ferritin and labeled bovine serum
albumin through the GBM.3–6 Furthermore, the injection of
anti-heparan sulfate proteoglycan antibodies led to albumi-
nuria in rats.7,8 Finally, in many experimental and human
glomerular diseases, such as diabetic nephropathy, minimal
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change disease, and membranous glomerulopathy, a
decreased expression of HS in the GBM was observed
when probed with our monoclonal anti-HS antibody
JM403,9–13 which in general correlated with the level of
urinary protein excretion. In contrast to HS, the expression
of agrin, the HS proteoglycan core protein most abundantly
present in the GBM,14 was not altered. In recent years it
became evident that the decreased expression of HS in
the GBM in several human and experimental proteinuric
diseases could be attributed to an increased glomerular
expression of heparanase.15–21 However, we showed that
intravenous injection of the bacterial HS-degrading
enzyme heparinase III in rats resulted in a near complete
loss of anionic sites in the GBM without the development
of proteinuria within 48 h.22 This finding challenged
the primary role of HS in the GBM in charge-selective
filtration.
Mammalian heparanase is synthesized as a 68-kDa pre-
proheparanase protein. After cleavage of an N-terminal signal
peptide, the latent proheparanase protein of 65 kDa is
formed, which has no enzymatic activity. The proheparanase
protein is proteolytically processed by cathepsin L in
endosomes/lysosomes, which yields an active heterodimer
consisting of a 8-kDa N-terminal subunit and a 50-kDa
C-terminal subunit.23,24 Cleavage of HS chains by heparanase
occurs at a few selective sites within a HS chain. Heparanase
cleaves the b(1–4) bond within HS, which requires N- and
6-O-sulfated moieties in a specific context as exemplified in
the trisaccharide sequence GlcNS6OS-a(1–4)–GlcA–b(1–4)-
GlcNS6OS.25,26 The role of heparanase in metastasis,
angiogenesis, and inflammation has been well-established.23
Recently, we generated transgenic mice overexpressing hu-
man heparanase (HPSE-tg).27 A first inventory of HPSE-tg
mice showed a very mild proteinuria compared with
controls. In the current study we analyzed the expression of
different HS domains, in particular in the kidney, in both
HPSE-tg and control mice of up to 8 months old by probing
with specific anti-HS antibodies. Furthermore, we deter-
mined the presence of glycosaminoglycan-associated anionic
sites in the GBM by probing with the cationic dye
cupromeronic blue. Finally, we evaluated glomerular ultra-
structure and renal function.
RESULTS
Renal overexpression of human heparanase in HPSE-tg mice
The expression of mammalian heparanase in kidneys
from HPSE-tg and control mice was evaluated (Figure 1),
which exclusively revealed mRNA (Figure 1a) and
protein (Figure 1b) expression of human heparanase in
HPSE-tg mice. Both the latent 65-kDa proheparanase protein
and the 50-kDa subunit of active heparanase could be
detected, whereas the 50-kDa protein was more abundantly
expressed (Figure 1b). Immunofluorescence staining of renal
sections revealed the expression of the human heparanase
protein in both tubuli and glomeruli of HPSE-tg mice
(Figure 1c).
Differential loss of distinct HS domains in HPSE-tg and
control mice
The expression of different HS domains in renal sections of
HPSE-tg and control mice was evaluated by probing with
specific anti-HS antibodies. We applied the monoclonal
antibody NAH46 recognizing N-acetylated unmodified HS
domains, which resembles the structure of the bacterial
polysaccharide K5,28 the monoclonal antibody JM403
recognizing HS domains containing N-unsubstituted gluco-
samine residues,29 and phage display-derived single-chain
antibodies recognizing sulfated HS domains (Table 1;
Figure 2). HS domains containing N-unsubstituted glucosa-
mine residues probed with JM403 were completely absent in
kidneys of HPSE-tg mice (Figure 2b) compared with controls
(Figure 2a). Note the loss of staining by JM403 along the
capillary wall in the GBM of HPSE-tg mice. In contrast, the
expression of N-acetylated unmodified HS domains probed
with NAH46, in different renal structures including the
GBM, was not different between control (Figure 2c) and
HPSE-tg mice (Figure 2d). There was a moderate to strong
expression of sulfated HS domains in the GBM of controls
probed with HS4C3, EV3B2, HS3A8, and AO4B08 (Figure 2e,
g, i, and k). The expression of these sulfated HS domains in
the GBM of HPSE-tg mice was either strongly decreased
(HS4C3; Figure 2f) or lost (EV3B2 and HS3A8; Figure 2h
and j), whereas the expression of the sulfated HS domain
defined by AO4B08 persisted (Figure 2l). The sulfated HS
domains defined by HS4E4 and LKIV69 that are not located
in the GBM of controls (Figure 2m and o), were also lost in
HPSE-tg mice (Figure 2n and p). An increased glomerular
dermatan sulfate or chondroitin sulfate (CS) expression
could serve as potential compensatory mechanisms for the
loss of HS in the GBM of HPSE-tg mice. Analysis with
Control Control
Control
HPSE-tg 65 kDa
50 kDa
HPSE-tg
HPSE-tg
Figure 1 | Renal overexpression of human heparanase in HPSE-tg
mice. (a) Heparanase mRNA expression analysis revealed a high
human heparanase mRNA expression in the kidney of HPSE-tg mice,
whereas no expression was observed in controls. (b) Western blot
analysis of kidney tissue lysates showed that both the latent 65-kDa
heparanase and the processed 50-kDa heparanase are expressed in
HPSE-tg mice but not in controls. (c) Immunofluorescence staining
demonstrated that heparanase is overexpressed in both glomeruli
and tubuli of HPSE-tg mice compared to controls. Original
magnification  40.
Kidney International (2008) 73, 278–287 279
MJ van den Hoven et al.: Heparanase overexpression and heparan sulfate loss o r i g i n a l a r t i c l e
specific antibodies revealed no glomerular expression of
dermatan sulfate in either HPSE-tg or control mice (data not
shown), while probing for CS with the anti-CS antibody
IO3H10 only revealed a hardly detectable glomerular staining,
which was similar for HPSE-tg mice and controls (Figure 2q
and r), and in line with previous findings.35 Table 2 summarizes
the morphological expression of the different HS/CS domains
in renal sections of HPSE-tg mice and controls.
Table 1 | Antibodies used in this study
Antibody Antibody isotype Preferred epitopes Source or reference
JM403 Monoclonal mouse IgM Anti-HS: GlcN van den Born et al.8,29
NAH46 Monoclonal mouse IgM Anti-HS: GlcNAc-GlcA Seikagaku, Tokyo, Japan
AO4B08 ScFv Anti-HS: GlcNS6S-IdoA2S Jenniskens et al.;30 Kurup et al.31
EV3B2 ScFv Anti-HS: GlcNS±6S-GlcA/IdoA Dennissen et al.32
HS3A8 ScFv Anti-HS: GlcNS6S-IdoA2S Dennissen et al.32
HS4C3 ScFv Anti-HS: GlcNS3S6S-GlcA/IdoA2S van Kuppevelt et al.33
HS4E4 ScFv Anti-HS: GlcNAc/GlcNS-IdoA Dennissen et al.;32 Kurup et al.31
LKIV69 ScFv Anti-HS: GlcNS-IdoA2S Wijnhoven et al.34
IO3H10 ScFv Anti-CS A, C, and E: Smetsers et al.35
HPA1 Rabbit IgG Anti-human heparanase ProsPecTany, Rehovot, Israel
MI91 Monoclonal hamster IgG Anti-agrin, N-terminus Raats et al.14
CS A, C, and E, chondroitin sulfate A, C, and E; GlcA, D-glucuronic acid; GlcN, N-unsubstituted glucosamine; GlcNS, N-sulfated glucosamine; HS, heparan sulfate; IdoA, L-iduronic
acid; 2S, 2-O-sulfated; 3S, 3-O-sulfated; 6S, 6-O-sulfated; ScFv, single-chain variable fragment antibody.
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Figure 2 | Transgenic overexpression of heparanase in HPSE-tg mice leads to differential loss of HS domains. Expression of HS domains
with N-unsubstituted glucosamine residues is especially found in the GBM of controls, as probed with antibody JM403 (a), whereas no
expression could be detected in the glomeruli of HPSE-tg mice (b). However, expression of unmodified N-acetylated HS domains in the
GBM, recognized by antibody NAH46, was similar in controls and HPSE-tg mice (c, d). There was a moderate to strong expression of sulfated
HS domains in the GBM of control kidneys, as probed with HS4C3, EV3B2, HS3A8, and AO4B08 (e, g, i, k). Expression of the sulfated HS
domains in the GBM of HPSE-tg mice was either strongly reduced (HS4C3) (f) or abolished (EV3B2 and HS3A8) (h, j), whereas expression
of the sulfated HS domains recognized by AO4B08 in the GBM of HPSE-tg mice was normal (l). Expression of sulfated HS domains that are not
located in the GBM of controls, but mainly in the Bowman’s capsule and tubular basement membrane (HS4E4 and LKIV69) (m, o) was
also absent in HPSE-tg mice (n, p). Glomerular expression of CS, which could serve as a compensatory mechanism for the glomerular loss
of HS in HPSE-tg mice, was hardly detectable in controls (q) and not increased in HPSE-tg mice (r). See also Table 2 for a summary of the
expression of HS/CS domains in the kidney. Original magnification  40.
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The differential loss of HS domains in renal sections of
HPSE-tg mice could be explained by locally different
concentrations of active mammalian heparanase. Therefore,
we treated renal sections of normal mice with active
recombinant human heparanase. Probing of heparanase-treated
renal sections with anti-HS antibodies revealed essentially the
same differential loss of HS domains as observed in HPSE-tg
mice (Figure 3). The HS domain containing N-unsubstituted
glucosamine residues defined by JM403, and the sulfated HS
domains defined by HS4C3, EV3B2, HS3A8, HS4E4, and
LKIV69, were either strongly decreased or completely lost
(Figure 3a–f). In contrast, the sulfated HS domain defined by
AO4B08 and the N-acetylated unmodified HS domain
defined by NAH46, resisted heparanase treatment (Figure
Table 2 | Renal expression of distinct HS domains in HPSE-tg and controls as probed with anti-HS antibodies
JM403 NAH46 HS4C3 EV3B2 HS3A8 AO4B08 HS4E4 LKIV69 IO3H10
Contr. Htg Contr. Htg Contr. Htg Contr. Htg Contr. Htg Contr. Htg Contr. Htg Contr. Htg Contr. Htg
GBM ++ – ++ ++ ++ ± + – ± – ± ± – – – – ± ±
Mesangium – – + + ++ ± + ± ± – ± ± – – – – – –
Bowman’s capsule ± – + + + – ++ – + – ++ ++ + – ++ ± ++ ++
TBM ± – + + ++ ± ++ – ++ – ++ ++ + – + – ++ ++
PTC – – + + ++ ± ++ – ++ – + + – – – – ++ ++
Blood vessels – – + + + – + – ++ – – – + – ++ – + +
Contr., control mice; GBM, glomerular basement membrane; HS, heparan sulfate; Htg, HPSE-tg mice; PTC, peritubular capillaries; TBM, tubular basement membrane;
++, strong staining; +, good staining; ±, moderate staining; and –, absent.
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Figure 3 | Treatment of normal mouse kidney sections or coated HS with recombinant active heparanase leads to differential loss
of HS domains. Expression of N-unsubstituted HS domains, probed with JM403 (a) and the highly sulfated HS domains, probed with
HS4C3, EV3B2, HS3A8, HS4E4, and LKIV69 (b–f), was either strongly decreased or lost after heparanase treatment. Expression of the sulfated HS
domain defined by AO4B08 (g) and the unmodified N-acetylated HS domain defined by NAH46 (h) persisted after exposure to heparanase.
Note that the differential loss of HS domains was comparable to the patterns of HS expression in HPSE-tg mice (compare with Figure 2 a–p).
(i) HS of bovine kidney coated in microtiter plates exposed to recombinant active heparanase at 0.3 or 2.5 mg ml1 for 3 h also revealed
a differential loss of HS domains. At 2.5mg ml1 a 93% decrease of the HS domain containing N-unsubstituted glucosamine residues defined
by JM403 and a 70–86% decrease for the sulfated HS domains defined by EV3B2, HS3A8, HS4E4, and LKIV69 can be calculated. The sulfated
HS domain defined by HS4C3 was reduced 45%, whereas the sulfated HS domain defined by AO4B08 was reduced 31%, and the
N-acetylated unmodified HS domain defined by NAH46 was reduced 9%. Original magnification  40.
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3g and h). Finally, we treated HS from bovine kidney, coated
in microtiter plates, with active mammalian heparanase at
two concentrations followed by probing with anti-HS
antibodies. This experiment confirmed the results obtained
in vivo in the HPSE-tg mice and in vitro on renal sections of
normal mice treated with active mammalian heparanase
(Figure 3i). The HS domains in enzyme-linked immunosor-
bent assay after treatment with heparanase, as defined by the
anti-HS antibodies, persisted in the following order NAH464
AO4B084HS4C34HS4E44LKIV694HS3A84EV3B24
JM403. Note that although in enzyme-linked immunosorbent
assay binding of AO4B08 decreased more (31%) than that of
NAH46 (9%), the binding of AO4B08 to tubular basement
membranes after HPSE digestion was still stronger compared
with NAH46. This can be explained by the fact that the staining
of AO4B08 to tubular basement membranes of control sections
was already much stronger than for NAH46.
Treatment of renal sections of HPSE-tg and control mice,
and treatment of coated HS, with the bacterial HS-degrading
enzyme heparinase III, resulted in the loss of all HS domains
(data not shown).
In addition to renal sections, we evaluated the expression
of HS domains in sections of spleen and liver of HPSE-tg and
control mice. This revealed similar data as obtained for the
kidney (data not shown).
In summary, overexpression of mammalian heparanase
leads to a differential loss of HS domains in the GBM, which
is similar for different tissues.
Loss of glycosaminoglycan-associated anionic sites in the
GBM does not lead to a clear renal phenotype
In addition to the analysis with anti-HS antibodies, we
visualized the number of glycosaminoglycan-associated
anionic sites in the GBM of HPSE-tg and control mice, by
probing with the cationic dye cupromeronic blue36 (Figure 4).
As expected, cupromeronic blue stained the GBM of controls,
which was most intense at the podocyte side as revealed by
black dots (Figure 4a and b), whereas occasionally some
residual cupromeronic blue staining was found in the GBM
of HPSE-tg mice, mainly at the endothelial side (Figure 4c
and d). Visual scoring of the number of black dots in the
GBM on several sections revealed aB5-fold reduction of the
number of glycosaminoglycan-associated anionic sites in
HPSE-tg mice compared with controls. To evaluate whether
there was a difference in overall turnover of HS in HPSE-tg
compared with control mice, we analyzed the presence of
glycosaminoglycans in the urine. Glycosaminoglycans were
present in the urine of 8/11 HPSE-tg mice and 4/8 control
mice (data not shown). Since we did not observe intracellular
accumulation of HS, this suggests that chronic overexpres-
sion of heparanase does not lead to an increased biosynthesis
and urinary secretion of HS.
It has been assumed that the charge-selective properties of
the capillary filter are dictated by the negatively charged HS
in the GBM. Therefore, we measured urinary albumin and
creatinine in HPSE-tg and control mice. It appeared that on
average the HPSE-tg mice (n¼ 11) showed a low, but
statistically significant higher level of albuminuria compared
with controls (n¼ 9), although the majority of HPSE-tg mice
had urinary albumin/creatinine ratios within the normal
range (Figure 5). Renal function, as measured by the
concentration of serum creatinine, did not significantly differ
between HPSE-tg mice (22.5 mM±1.8) and controls
(21.5 mM±1.5) as found previously.27 Finally, we examined
the glomerular ultrastructure of HPSE-tg (n¼ 6) mice and
controls (n¼ 4) (Figure 6). No differences could be observed
between controls (Figure 6a and b) and HPSE-tg mice (Figure 6c
and d). The appearance of GBM thickness, podocyte foot
processes architecture, glomerular endothelium, and mesangium
was similar for HPSE-tg and control mice.
In summary, despite the chronic overexpression of
heparanase, leading to a B5-fold decrease of glycosamino-
glycan-associated anionic sites in the GBM, HPSE-tg mice
show a normal renal function and architecture without
development of severe albuminuria.
DISCUSSION
In recent years it has been shown that in several (experimental)
proteinuric diseases heparanase is upregulated, which was
a b
c d
Figure 4 | Analysis of the number of glycosaminoglycan-
associated anionic sites in the GBM of HPSE-tg and control mice.
(a, b) Glycosaminoglycans, visualized by the cationic dye
cupromeronic blue, were observed as a dotted-like pattern in the
GBM of control mice, which was most intense at the side of the
podocytes. (c, d) In the GBM of HPSE-tg mice, cupromeronic blue
staining was strongly decreased, although occasionally some staining
remained, mainly at the endothelial site of the GBM. Semiquantitative
analysis (by counting the black dots per GBM surface area from 10
random sections of three individual mice of each mice strain)
revealed a B5-fold decreased binding of cupromeronic blue in the
GBM of HPSE-tg mice compared with control mice. Original
magnification  10 000 (a, c); original magnification  20 000 (b, d).
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associated with a decreased expression of HS in the
GBM.15–21 It has been postulated that this heparanase-
mediated loss of HS in the GBM leads to proteinuria.
In this study we show that chronic and systemic
overexpression of heparanase leads to the differential loss of
specific HS domains from the GBM. An unmodified N-
acetylated HS precursor domain (NAH46) and one sulfated
HS domain (AO4B08) persisted, whereas another sulfated
domain persisted partially (HS4C3). Moreover, this differ-
ential loss of HS domains was similar in several tissues, that
is, kidney, spleen, and liver. Heparanase only cleaves at
specific positions within one HS chain, which results in small
HS fragments of different sizes.25,37,38 Three different
explanations can be postulated for the differential loss of
HS domains after heparanase cleavage. First, the HS domains
that (partially) persist may be present in the remnants of HS
chains that remain bound to the core protein after cleavage
by heparanase, and which do not contain sites susceptible to
cleavage by heparanase. Second, the unmodified N-acetylated
HS domain reflects the first structure after initial HS
biosynthesis,1 whereas the domain defined by antibody
AO4B08 may be the first sulfated HS domain arising. Indeed,
biochemical analysis of HS of the whole liver and kidney of
HPSE-tg mice revealed two to threefold shortened HS chains,
which were relative highly 2-O-sulfated compared with
controls27,39 (and JP Li et al., unpublished observations).
So, the continuous action of heparanase may lead to trimmed
HS chains consisting of HS domains that do not contain sites
susceptible to cleavage by heparanase. However, we showed
no significant higher urinary secretion of HS in HPSE-tg
mice or glomerular intracellular accumulation of sulfated HS,
making this option less likely. Third, but less likely, the
existence of a subgroup of native HS chains solely consisting
of N-acetylated domains defined by NAH46 and sulfated
domains defined by AO4B08 and/or HS4C3 (Figure 7).
We showed the loss of HS domains with N-unsubstituted
glucosamine residues in the GBM of patients with overt
diabetic nephropathy, which was associated with an increased
glomerular expression of heparanase.20 In agreement with
our current findings, we also could show that the expression
of unmodified N-acetylated HS domains in the GBM of
diabetic patients was similar to healthy controls (Wijnhoven
et al., submitted). The ratio of expression of HS domains
with N-unsubstituted glucosamine residues (JM403) versus
unmodified N-acetylated HS domains (NAH46) in the GBM,
may be a measure for the glomerular activity of heparanase,
which most likely is distinct from other mechanisms leading
to loss of HS in the GBM during proteinuric diseases.40
In a first inventory of HPSE-tg mice, we observed a mild
level of proteinuria.27 Since this could be explained by the
presence of the sulfated HS domains defined by AO4B08 and
HS4C3 in the GBM of HPSE-tg mice as we show now, we
measured the total content of glycosaminoglycan-associated
anionic sites in the GBM. Probing with the cationic dye
cupromeronic blue revealed a fivefold reduction of glycosa-
minoglycan-associated anionic sites in the GBM of HPSE-tg
mice. The staining of the GBM by AO4B08 is weak in the
GBM of both HPSE-tg and control mice, whereas the staining
of the GBM by HS4C3 is strongly reduced in the GBM of
HPSE-tg mice. Nevertheless, the sulfated HS domains defined
by AO4B08 and HS4C3 may be responsible for the remaining
glycosaminoglycan-associated anionic sites in the GBM of
HPSE-tg mice, as revealed by cupromeronic blue staining.
Assessment of renal function, by measuring serum creatinine
levels, albuminuria, and glomerular ultrastructure of the
mice used for HS analysis, revealed only a marginal, although
statistically significant, level of albuminuria. Furthermore,
renal function of HPSE-tg mice was normal and glomerular
architecture of HPSE-tg mice and controls was similar. In our
first inventory, we also found a normal renal function in
HPSE-tg mice, but then we had the impression that there was
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Figure 5 | Urinary albumin/creatinine ratios in HPSE-tg and
control mice. In HPSE-tg mice, only a mild but significant increase in
urinary albumin excretion could be detected using radial
immunodiffusion. However, the majority of HPSE-tg mice showed a
normal albumin/creatinine ratio; *Po0.05.
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Figure 6 | Glomerular ultrastructure of HPSE-tg and control mice.
A normal architecture of the glomerular filtration barrier was
observed in all kidney tissue sections of control mice (a, b) and
HPSE-tg mice (c, d). Original magnification  5000 (a, c); original
magnification  15 000 (b, d).
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a diffuse local podocyte foot process effacement in HPSE-tg
mice,27 but this was not substantiated in the current stock of
mice. This may be explained by further inbreeding of the
HPSE-tg mice in the C57BL/6 background, whereas it is
important to stress that foot process effacement and
proteinuria not always have to correlate.41 Nevertheless, we
show that glomerular overexpression of heparanase, which is
relevant for several (experimental) glomerular diseases,15–21
does not lead to significant albuminuria despite the B5-fold
loss of glycosaminoglycan-associated anionic sites in the
GBM. These data question the primary role of HS in the
GBM in determining the charge-selective properties of the
capillary filter. Furthermore, maturation and morphology of
podocytes, glomerular endothelium, and mesangium appear
not to be influenced by the lack of the majority of HS in the
GBM and other glomerular structures.
Recently, other studies also questioned the primary role of
HS in the GBM in charge-selective filtration. Mice with
podocytes lacking agrin did not develop proteinuria nor
revealed an aberrant glomerular architecture.42 Mice with
podocytes lacking the HS polymerase EXT1 did develop
glomerular ultrastructural abnormalities and podocyte loss
during the first 8 months, whereas a mild albuminuria
became evident at an age of 8 months.41 Rats injected with
the bacterial HS-degrading enzyme heparinase III, leading to
the nearly complete loss of glycosaminoglycan-associated
anionic sites in the GBM, did not develop albuminuria
within the observation period of 48 h.22 Mice deficient in
perlecan and/or collagen XVIII, HS proteoglycan core
proteins, mainly expressed in the mesangium and Bowman’s
capsule, also did not develop glomerular abnormalities and
albuminuria under physiological conditions.43,44
Although our current study differs in the approach from
the studies mentioned above, fundamentally, they all exclude
a primary role of HS in charge-selective filtration. However,
in our opinion, we can still not exclude a role for glomerular
expression of heparanase and loss of HS in the GBM in the
development of proteinuria. We propose two possible
mechanisms that are compatible with the current data. In
the first sequential mechanism, the heparanase-mediated
release of HS fragments or HS-bound factors from the GBM
in a situation with glomerular pathology may induce
processes leading to or enhancing proteinuria. This pathway
is not established in the HPSE-tg, podocyte-specific agrin-
and EXT1-deficient mice, since chronic constitutive absence
of HS in the GBM under physiological conditions does not
N-acetylated HS domains (NAH46)
Sulfated HS domains (AO4B08)
Sulfated HS domains (EV3C3, HS3A8, HS4E4, LKIV69)
Heparanase cleavage site
Agrin core protein
Linker domain
Sulfated HS domains (HS4C3)
N-unsubstituted HS domains (JM403)
a
b
c
Figure 7 | Possible explanations for the differential loss of HS domains observed after cleavage by heparanase. A differential loss of HS
domains was observed after in vivo and in vitro cleavage of HS by heparanase, which may be explained by three different possibilities.
(a) Unmodified N-acetylated domains (NAH46) and the sulfated domains recognized by AO4B08 may be remnants of HS after cleavage by
heparanase and are close to the core protein. The epitope defined by HS4C3 is not fully resistant to heparanase cleavage and is therefore
strongly decreased but not absent, whereas the N-unsubstituted domains, recognized by JM403, and the sulfated domains defined by EV3B2,
HS3A8, HS4E4, and LKIV69 are lost after degradation of HS by heparanase. (b) HS biosynthesis is not sufficient due to constant trimming of the
HS chains by the continuous action of heparanase in HPSE-tg mice, yielding the unmodified N-acetylated HS domains (NAH46) and the sulfated
HS domains (AO4B08) that are not susceptible to heparanase cleavage. HS chains may be modified due to constant degradation by
heparanase. Only the unmodified N-acetylated HS domains (NAH46) and the AO4B08 domains can be synthesized and are resistant to cleavage
by heparanase. (c) Native HS chains exist that solely consist of N-acetylated domains and sulfated domains as defined by AO4B08 are resistant
to cleavage by heparanase, since they lack cleavage sites.
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allow the binding of such growth factors or inflammatory
mediators and subsequent release of HS fragments or HS-
bound factors. The 48-h period as tested for healthy rats
injected with heparinase III may have been too short to
execute the pathological processes induced by the release of
HS fragments or HS-bound factors. In the absence of a
proinflammatory microenvironment, HS loss does not lead
to pathological consequences. In other words, a single hit is
not sufficient for development of proteinuria. Second,
assuming such a multi-hit mechanism, the heparanase-
mediated loss of HS in the GBM in combination with
additional pathological events/signals, like for example local
production of angiotensin II, ROS or cytokines, may lead to
activation of glomerular cells and development of proteinuria.
In all studies mentioned above, only one signal was manipu-
lated, that is, the loss of HS in the GBM. Although our study
closely resembles the actual situation of various glomerular
diseases by forcing heparanase-mediated HS loss in the GBM,
this occurs under non-pathogenic conditions. See van den
Hoven et al.21 for additional discussion on this issue.
That heparanase activity has relevance for development of
proteinuria can be derived from earlier studies, which
revealed that specific inhibition of heparanase in a pro-
inflammatory situation, like passive Heymann nephritis and
experimental anti-GBM nephritis, significantly reduced the
development of proteinuria.17,45 More definitive studies are
required to elucidate the role of heparanase and HS in the
development of proteinuria. Proof for this assumption of a
multi-hit genesis of proteinuria has to come from experi-
mentally induced glomerular diseases in different models, in
which heparanase or HS expression is manipulated. In this
respect, induction of proteinuria by, for example, streptozo-
tocin in HPSE-tg mice, in HPSE-deficient mice, or in mice
with HPSE-, agrin- or EXT1-deficient podocytes, definitely
will give more insight in the importance of heparanase-
mediated loss of HS in the pathogenesis of proteinuria.
MATERIALS AND METHODS
Transgenic heparanase-overexpressing mice
HPSE-tg and control mice with a mixed background (C57BL/6
(90–95%) and BALB/c (5–10%)) were generated and genotyped as
described.27 Kidney tissue, urine, and serum were obtained from
3- to 12-month-old mice. The housing and handling of the animals
were approved by the local animal ethics committees.
Analysis of creatinine, albumin and HS in urine and blood
samples
Urinary and serum creatinine were measured enzymatically (Roche
Diagnostics, Penzberg, Germany). Serum creatinine was used as a
measure for renal function. Urinary albumin was measured by radial
immunodiffusion,12,46 using goat antiserum against mouse albu-
min47 and purified mouse albumin (Sigma, Zwijndrecht, The
Netherlands) as a standard. Urinary albumin excretion was
expressed as the ratio mg albumin/mg creatinine. The presence of
glycosaminoglycans in the urine was determined after separating
urinary glycosaminoglycans by agarose gel electrophoresis followed
by a combined azure A-silver staining.48
RNA isolation, reversed transcription, and PCR
Total RNA was extracted from renal cortex using the RNeasy mini-
kit (Qiagen Benelux, Venlo, The Netherlands). cDNA was prepared
by reverse transcription of 1 mg RNA using oligo(dT) primers
(Invitrogen, Breda, The Netherlands). Heparanase cDNA was
amplified with primers specific for the human heparanase gene.
Forward primer (F): 50-caagaaggaatcaacctttgaag-30, Reversed primer
(R): 50-gtagtccaggagcaactgag-30 using platinum polymerase chain
reaction Supermix (Invitrogen). The expression of mouse b-actin was
included as a control; F: 50-gtgggccgctctaggcaccaa-30, R: 50-ctctttgatgtc
acgcacgatttc-30. Polymerase chain reaction conditions were as follows:
denaturation at 951C for 3 min, followed by 40 cycles of 951C for 15 s,
571C for 30 s, and 721C for 30 s, and finally elongation at 721C for
10 min. Polymerase chain reaction products were separated on a 2%
agarose gel and visualized with ethidium bromide.
Western blot analysis
Renal cortex was dissolved in lysis buffer containing 50 mM Tris-HCl
(pH 8), 150 mM NaCl, 0.5% Triton X-100 (Sigma), and ethylene-
diamine tetraacetic acid-free protease inhibitors (Roche Almere The
Netherlands). Heparanase was concentrated by incubating equal
amounts of total protein overnight at 41C with heparin–agarose
beads (Sigma).24 The beads were washed twice in phosphate-
buffered saline (PBS), boiled in Laemmli sample buffer, and resolved
by sodium dodecyl sulfate-polyacrylamide gel electrophoresis.
Proteins were transferred to a polyvinylidene difluoride membrane
(Bio-Rad Veenendaal The Netherlands). Blots were blocked with 1%
Boehringer blocking reagent (Roche) in PBS. Heparanase was
detected by incubation with rabbit polyclonal antibody HPA1
(1:700; ProsPecTany Technogene, Rehovot, Israel) followed by a goat
anti-rabbit peroxidase-conjugated antibody (1:8000; Santa Cruz
Heer Hugo Waard, The Netherlands). Heparanase protein was
visualized using enhanced chemiluminescence reagent (Perbio
Science, Etten-Leur, The Netherlands) and ECL hyperfilm (Amer-
sham Biosciences, Buckinghamshire, UK).
Antibodies, immunofluorescence staining, and treatment
with active heparanase
The expression of different HS domains, chondroitin sulfate,
dermatan sulfate, agrin core protein, and heparanase was detected
by specific antibodies as listed in Table 1. The phage display-derived
single-chain antibodies (scFv) were prepared as described.32,30,33
Mouse kidney sections were fixed in acetone for 10 min at 41C and
then incubated for 1 h at room temperature with primary
antibodies. For monoclonal mouse antibodies, sections were first
blocked using the mouse-on-mouse kit (Vector Laboratories Inc.,
Burlingame, CA, USA). Sections were washed with PBS and
incubated with secondary antibodies for 1 h at room temperature.
The scFv antibodies were detected by the rabbit anti-Vesicular
Stomatitis Virus (VSV) antibody (1:500; MBL, Nagoya, Japan). The
mouse IgM antibodies, hamster IgG antibody, and rabbit IgG
antibodies were, respectively, detected by goat anti-mouse IgM Alexa
488 (1:200; Invitrogen), goat anti-hamster fluorescein isothiocyanate
(1:400; MP Biomedicals, Eschwege, Germany) and goat anti-rabbit
IgG Alexa 488 (1:200; Invitrogen). All antibodies were diluted in
PBS supplemented with 2% (w/v) bovine serum albumin and 0.05%
(v/v) Tween-20 (Sigma). Normal goat serum (4%) was added to all
secondary antibodies. Finally, sections were washed in PBS,
embedded in Vectashield mounting medium H-1000 (Vector
Laboratories Inc.), and examined with a Zeiss Axioskop microscope
(Carl Zeiss BV, Sliedrecht, The Netherlands).
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To mimic the effect of in vivo heparanase overexpression in vitro,
renal cryosections of normal mice were incubated with active
recombinant human heparanase (0.22 mg ml1) in 50 mM sodium
acetate buffer (pH 5) for 2 h at 371C. Then, sections were washed in
PBS, fixed, and stained as described above.
Digestion of HS by recombinant heparanase in enzyme-
linked immunosorbent assay
Flat bottom 96-well plates (Nunc A/S, Roskilde, Denmark) were
coated with 5 mg per well HS from bovine kidney (Seikagaku, Tokyo,
Japan) in PBS overnight at 41C. Wells were left untreated or
incubated with 0.3 or 2.5 mg ml1 active recombinant human
heparanase in 50 mM sodium acetate buffer (pH 5) for 3 h at
371C. Plates were washed with PBS with 0.5% Tween and blocked
with PBS with 1% gelatin for 1 h. Plates were washed with PBS/
Tween and incubated with anti-HS antibodies for 1 h in PBS/gelatin.
Dilutions of anti-HS antibodies were chosen from serial dilutions on
coated HS that allowed detection of a decrease in HS. Anti-HS
antibody binding was detected by incubating with the appropriate
horseradish peroxidase-conjugated antibodies in PBS/gelatin for 1 h.
Finally, the plates were washed with PBS/Tween and incubated with
tetramethylbenzidine solution (SFRI Laboratories, Berganton,
France). After 15 min, the reaction was stopped with 2 M H2SO4
and absorption was measured at 450 nm.
Visualization of glycosaminoglycan-associated anionic sites
by cupromeronic blue staining
Glycosaminoglycan-associated anionic sites were visualized by the
critical electrolyte concentration method as described.36 We have
shown previously that this staining method is rather specific for HS
because heparinase III treatment abolished cupromeronic blue staining
in the GBM, whereas staining was not influenced by chondroitinase
ABC treatment.22,49 Pieces of cortex were fixed for 24 h in 25 mM
sodium acetate (pH 5.6) containing 2.5% (v/v) glutaraldehyde, 0.2 M
MgCl2, and 0.2% (w/v) cupromeronic blue (Seikagaku). Subsequently,
tissue was washed three times with fixing solution and three times with
water containing 1% (w/v) Na-tungstate. Tissue was dehydrated by
sequentially incubating in solutions with increasing concentrations of
ethanol containing 1% Na-tungstate. After incubation in 100% ethanol,
tissue was incubated in propylene oxide, followed by incubation with
50% (v/v) propylene oxide and Epon for 16 h, and with 100% (v/v)
Epon for a subsequent 16 h. Finally, tissue was embedded by
sequentially increasing the temperature (37, 45, and 601C for 24 h
each). Ultra-thin sections were prepared and examined with a Jeol
TEM 1010 microscope (JEOL, Tokyo, Japan).
Determination of glomerular ultrastructure by transmission
electron microscopy
Pieces of cortex were fixed in 2.5% glutaraldehyde dissolved in 0.1 M
sodium cacodylate buffer, pH 7.4, for 7 days at 41C. After washing in
cacodylate buffer, tissue was postfixed in palade-buffered 2% OsO4
for 1 h, dehydrated, and embedded in Epon 812, Luft’s procedure
(Merck, Darmstadt, Germany). Ultra-thin sections (90 nm) were
stained with 4% uranyl acetate for 45 min, followed by lead citrate
for 5 min at room temperature. Sections were examined with a Jeol
1200 EX2 electron microscope (JEOL).
Statistical analysis
Significance was evaluated by the non-parametric Mann–Whitney U-test
using GraphPad Prism 4.0. (GraphPad Software Inc., San Diego, CA,
USA). P-valuesp0.05 were considered statistically significant.
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